Oxford Cannabinoid Tech.Holdings Update on combined Clinical Trial Application (4579M)

TIDMOCTP

RNS Number : 4579M

Oxford Cannabinoid Tech.Holdings

12 January 2023

Oxford Cannabinoid Technologies Holdings plc

("OCTP" or the "Company")

Update on combined Clinical Trial Application for Phase I Clinical Trials

Further to the Company's announcement of 5 January 2023, OCTP confirms that the REC review meeting, an important element of the combined Clinical Trial Application for Phase I clinical trials for its lead programme OCT461201, took place yesterday. The ongoing review process is being undertaken in parallel by the Wales Research Ethics Committee ("REC") and the UK Medicines and Healthcare Products Regulatory Agency ("MHRA").

The Company will provide a further update on the outcome of the review in due course.

The Directors of the Company accept responsibility for the content of this announcement.

Enquiries:

 
 Oxford Cannabinoid Technologies    [phone] 
  Holdings plc                       [e-mail] 
  Clarissa Sowemimo-Coker (CEO) 
 Cairn Financial Advisers LLP 
  Emily Staples                       [phone] 
  Jo Turner                           [phone] 
 Axis Capital Markets Limited 
  Kamran Hussain                      [phone] 
  Richard Hutchison 
 
  finnCap Ltd 
  Geoff Nash/Fergus Sullivan          [phone] 
  Nigel Birks (ECM) 
 
  Walbrook PR Limited                 [phone] 
  Paul Vann/Nick Rome                 [phone] 
                                      [e-mail] 
 

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company of a pharmaceutical Group developing prescription cannabinoid medicines targeting the U$ multi-billion global pain market.

OCTP currently has a portfolio of four drug development programmes. Its lead compound, OCT461201, will initially target neuropathic and visceral pain (including irritable bowel syndrome ("IBS") and chemotherapy induced peripheral neuropathy ("CIPN")), with Phase 1 clinical trials, aimed at demonstrating safety and tolerability [in humans], due to commence in the near term. Trial results are expected in Q2 2023. The global market for CIPN alone was valued at US$1.61bn in 2020 and is forecast to reach US$2.37bn by the year 2027.

OCTP's drug development pipeline comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and potentially other therapeutic areas. Having established an exclusive license agreement with Canopy Growth Corporation for their entire pharmaceutical cannabinoid derivative library, OCTP now has a portfolio of over 400 derivatives and intellectual property rights including 14 patent families and associated research data.

OCTP has a clearly defined path to commercialisation, revenues and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence. OCTP's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identi ed by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements re ect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RESKFLFFXFLZBBK

(END) Dow Jones Newswires

January 12, 2023 02:00 ET (07:00 GMT)